NICE Issues Positive Recommendation for Xtandi (Enzalutamide)
The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD) recommending Xtandi (enzalutamide) within its marketing authorisation as an option for the treatment of metastatic hormone-relapsed prostate cancer in adults whose disease has progressed during or after docetaxel containing chemotherapy[i].
This announcement follows issuance of a first Appraisal Consultation Document (ACD) in October 2013[ii] and a second one in January 2014[iii]. The latter ACD included a restriction on the use of enzalutamide post-abiraterone[iii], which, following consultation, has been removed[i].
“I am delighted with this decision from NICE — this is great news for clinicians and will benefit many patients” comments Dr Heather Payne, Consultant in Clinical Oncology at University College Hospital. “Enzalutamide represents an important breakthrough in the management of this disease and has demonstrated survival benefit whilst offering patients improved quality of life. Metastatic castrate-resistant prostate cancer affects thousands of men in the UK and today’s FAD will allow patients access to a valuable treatment option on the NHS.”
Prostate cancer is the most common cancer amongst males in England, with more than 34,000 new cases diagnosed annually, a proportion of whom will go on to develop castrate-resistant disease[iv]. The recommendation is based on data from the pivotal Phase III AFFIRM trial which demonstrated that treatment with enzalutamide improved overall survival by an average of 4.8 months compared to placebo — a 37% reduction in the risk of death[v].
Dr Alan McDougall, Medical Director at Astellas Pharma Ltd comments: “We welcome the latest decision by NICE, and are pleased that the restriction in the second ACD has been removed. We believe that all appropriate patients who can benefit should have access to enzalutamide on the NHS which will allow clinicians to make the best treatment decision for their patients. ”
Marketing Authorisation was granted to enzalutamide within Europe in June, 2013[vi]. In Scotland, enzalutamide is recommended within its licensed indication on the NHS following approval from the Scottish Medicines Consortium (SMC) in November 2013[vii]. Similarly with the pending issuance of this NICE Guidance in June, enzalutamide will be recommended within its licensed indication, with NICE noting that the prior use of abiraterone is not covered by this guidance[i].
References
[i] The National Institute for Health and Care Excellence, FAD for enzalutamide, available at www.nice.org.uk/, last accessed May 2014.
[ii] The National Institute for Health and Care Excellence, first ACD for enzalutamide, available at www.nice.org.uk/, last accessed Jan 2014.
[iii] The National Institute for Health and Care Excellence, second ACD for enzalutamide, available at www.nice.org.uk/, last accessed April 2014.
[iv] Prostate Cancer UK, Prostate Cancer Facts and Statistics, available at http://prostatecanceruk.org/information/prostate-cancer-facts-and-figures, last accessed April 2014.
[v] Scher H I, et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy, N Engl J Med 2012; 367:1187–1197.
[vi] European Medicines Agency, Xtandi (enzalutamide) Summary of Product Characteristics, available at www.medicines.org.uk/emc/medicine/27912/SPC_Product_Information/human/002639/WC50014499 6.pdf last accessed April 2014.
[vii] SMC recommendation for enzalutamide (Xtandi), Scottish Medicines Consortium website, available at www.scottishmedicines.org.uk/Home, last accessed April 2014.
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance